A total of 28.1% (9/32) of patients with ICC were positive for both TIGIT and PD-L1, whereas 100.0% (1/1) of patients with ECC and 75.0% (6/8) of patients with GBC were positive for both TIGIT and PD-L1. This evidence concerns the gene CD274 and intrahepatic cholangiocarcinoma.